Nuvation Bio Inc.
NUVB · Healthcare · $2.2B mkt cap · FY2025 filings · No moat ·
Doesn't clear the bar
The five investor questions
2024–2025 (latest 2 aligned FYs; v3 window cap 5): revenue $7.9M to $62.9M, increasing; diluted EPS -2.11 to -0.60, increasing. Two-year history is scoreable but carries less confidence than a full-cycle record.
Not enough years of gross-margin data to score pricing power.
Median ROIC -17.8%, above the 12% hurdle in 0% of years.
Net cash position — no leverage risk.
Owner earnings changed trend unclear over up to the ten most recent annual observations.
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- Not reported
- Unavailable — insufficient owner-earnings data
- Unavailable — insufficient growth-model data
- $6.42
- No price data
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. Flag status unavailable — four adjacent recent FY revenue observations are required.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
Fundamentals
We couldn't reach the fundamentals service just now, so we won't show a stale or guessed series for NUVB. Try again shortly.
Visual explainers
The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.
Moat Score history
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
This machine-readable surface covers SEC ownership filings from 2003; it does not represent earlier paper-era records.
Records still being gathered — partial as of retrieval Aug 11, 2026.
Trailing-12-month totals and the 90-day cluster result are withheld because this issuer walk is incomplete.
No reported Form 4 rows were captured for NUVB; the incomplete walk cannot establish zero activity, zero counts, or a negative cluster result.
A filing source-event date will appear when a Form 4 row is captured.
Retrieved .
Healthcare context
#430 of 728 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #428RLYB RALLYBIO CORPORATION37.3 out of 100, No moatNo moat
- #429EQ EQUILLIUM, INC.37.3 out of 100, No moatNo moat
- #431GLUE Monte Rosa Therapeutics, Inc.37.3 out of 100, No moatNo moat
- #432PRME Prime Medicine, Inc.37.3 out of 100, No moatNo moat
Compare NUVB with its nearest peers →All Healthcare companies on the Index →
Common questions about NUVB
- Does Nuvation Bio Inc. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores Nuvation Bio Inc. (NUVB) 37.3 out of 100 — below the Shallow-moat bar, so no moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 70, pricing power not measurable from the filings, returns on capital 0, balance-sheet safety 55, capital allocation 24.
- How has NUVB's Moat Score changed over time?
- The record logs 16 readings since Jul 17, 2026; the latest reads 37.3 out of 100 (no moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.